Physician profile
Yasuhiro Maeda
NPI 1871558007
$4,910.07
in general payments reported to CMS, 2019-2025
40 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $74.35 · 2021: $139 · 2022: $551 · 2023: $836 · 2024: $1,314 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,653 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,653.41 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $514.83 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Abbvie INC. | $478.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $431.27 | 2019-2025 | |
| Lilly USA, LLC | $335.70 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Eisai INC. | $299.55 | 2023-2025 | |
| Tg Therapeutics, INC. | $295.65 | 2023-2025 | |
| Pfizer INC. | $214.71 | 2023-2025 | |
| Genentech USA, INC. | $193.46 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Argenx US, INC. | $178.62 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $175.65 | 2024-2025 | Zeposia |
| Merz Pharmaceuticals, LLC | $150.39 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Janssen Biotech, INC. | $137.33 | 2022-2025 | Tremfya |
| Acadia Pharmaceuticals INC | $130.41 | 2024-2025 | Nuplazid, Daybue |
| Lundbeck LLC | $117.49 | 2024-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $105.75 | 2023-2025 | Rytary, Crexont |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasuhiro Maeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.